The CryoPatch® SG Pulmonary Human Cardiac Patch is derived from human pulmonary valve and artery tissue aseptically recovered from qualified donors. The patch is treated with an antimicrobial solution, and treated to remove the cells and cellular debris that have not already been removed during the post mortem period. harvesting, and the antimicrobial process. The patch is cryopreserved in a tissue culture medium, containing a cryoprotectant, within the innermost pouch of a three pouch packaging system. The packaging system not only withstands ultra cold temperatures, but also allows for aseptic introduction of the patch into the operating room. Supercooling by liquid nitrogen boost is begun prior to crystallization to minimize ice crystal damage to the patch matrix. Finally, the patch is transferred for long term storage at or below -135° C.

CryoPatch® SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.

Implantation of the CryoPatch SG Pulmonary Human Cardiac Patch reduces the risk for induction of HLA class I and class II alloantibodies, based on Panel Reactive Antibody measured at up to one year, compared to standard-processed pulmonary cardiac tissues. Data have not been provided to evaluate the effect of reduced HLA class I and class II alloantibodies on the long-term durability, or long-term resistance to rejection by the patient, of the CryoPatch SG.

AI/ML Overview

The provided text does not contain acceptance criteria or a study that proves the device meets specific acceptance criteria in the way typically found in device performance studies for AI/software devices.

Instead, this document is a 510(k) summary for a human cardiac patch (CryoPatch® SG Pulmonary Human Cardiac Patch), which is a physical biological device, not an AI or software model. The "studies" mentioned refer to evaluations of the biological and mechanical properties of the patch, and its substantial equivalence to predicate devices, rather than performance metrics like sensitivity, specificity, or AUC as one would expect for an AI system.

Here's a breakdown of why this document doesn't fit the requested criteria and what information it does provide:

A table of acceptance criteria and the reported device performance: This is not present for performance metrics. The document states: "CryoPatch SG has undergone biomechanical, histological, DNA content, and decellularization evaluation. In addition, a large animal study and clinical data support the substantial equivalence of the device to previously marketed devices." These are general categories of testing, not specific acceptance criteria with quantifiable outcomes. The closest to a "performance metric" is the statement regarding HLA class I and class II alloantibodies: "Implantation of the CryoPatch SG Pulmonary Human Cardiac Patch reduces the risk for induction of HLA class I and class II alloantibodies, based on Panel Reactive Antibody measured at up to one year, compared to standard-processed pulmonary cardiac tissues." However, no specific acceptance threshold or numerical performance is given.
Sample sized used for the test set and the data provenance: No information on sample sizes for specific tests is provided, nor data provenance in terms of country of origin or retrospective/prospective nature for these evaluations. It mentions "clinical data" and a "large animal study" generally.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable. Ground truth for a physical patch would likely be established through laboratory analyses, animal models, and clinical follow-up by medical professionals (surgeons, pathologists), but the document does not detail this process in the context of "experts" as in AI ground truth assessment.
Adjudication method for the test set: Not applicable.
If a multi reader multi case (MRMC) comparative effectiveness study was done: Not applicable. This is not a diagnostic device where human readers would interpret outputs.
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable. This is not an algorithm.
The type of ground truth used: For a physical medical device like this, "ground truth" would be established through:
- Histological, DNA content, and decellularization evaluations: These are laboratory analyses using established scientific methods to assess the tissue's properties.
- Large animal study: In vivo performance in an animal model.
- Clinical data: Outcomes in human patients.
  The document doesn't provide specifics on how this ground truth was used to establish criteria or measure performance against them.
The sample size for the training set: Not applicable. This is not an AI/ML device.
How the ground truth for the training set was established: Not applicable.

In summary, the provided document describes a physical medical device (a human cardiac patch) and its 510(k) clearance summary. It focuses on demonstrating substantial equivalence to predicate devices through various biological and biomechanical testing, animal studies, and clinical data, rather than meeting acceptance criteria for an AI or software device's performance.

Summary

{0}------------------------------------------------

CryoPatch® SG Pulmonary Human Cardiac Patch 510(k) Submission CryoLife, Inc.

510(K) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accord MIG Mill (2009 requirements of 21 C.F.R. § 807.92.

Submitter:	CryoLife, Inc.1655 Roberts Blvd., NWKennesaw, GA 30144(770) 419-3355
Contact Person:	John D. FerrosDirector, Regulatory Affairs
Device Names:	Device Trade Name:Common/Usual Name:Classification Name:	CryoPatch® SG Pulmonary Human Cardiac PatchAllograft PatchIntracardiac patch or pledget
Intended Use:	CryoPatch® SG Pulmonary Human Cardiac Patch is indicated for repair or reconstructionof the right ventricular outflow tract.

Predicate Devices:

Device	Company	510 (k) Number(s),Clearance Date	ProductCode
MatrACELLTMPulmonary Artery PatchAllograft	LifeNet HealthVirginia Beach, VA	K081438 - 10/17/2008	DXZ
CryoValve® SGPulmonary Valve (andConduit).	CryoLife, Inc.Kennesaw, GA	K033484 - 02/07/2008K083106-02/06/2009	OHA

Device Description:

CryoPatch® SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.

Testing Supporting Substantial Equivalence:

CryoPatch SG has undergone biomechanical, histological, DNA content, and decellularization evaluation. In addition, a large animal study and clinical data support the substantial equivalence of the device to previously marketed devices.

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three tail feathers, representing the three levels of government: federal, state, and local. The eagle is enclosed in a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-0609 Silver Spring, MD 20993-0002

AUG 0 7 2009

CryoLife, Inc. c/o Mr. John D. Ferros Director, Regulatory Affairs 1655 Roberts Boulevard, NW Kennesaw, GA 30144

Re: K091626

Trade/Device Name: CryoPatch® SG Pulmonary Human Cardiac Patch Regulation Number: 21 CFR 870.3470 Regulation Name: Intracardiac Patch or Pledget Regulatory Class: Class: II (two) Product Code: DXZ Dated: June 1, 2009 Received: June 3, 2009

Dear Mr. Ferros:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{2}------------------------------------------------

Page 2 - Mr. John D. Ferros

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Anna R. Vicker

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Indications for Use

510(k) Number (if known): K091626

Device Name: CryoPatch® SG Pulmonary Human Cardiac Patch

Indications For Use: Indicated for repair or reconstruction of the right ventricular outflow tract.

Prescription Use (Part 21 CFR 801 Subpart D) AND/OR .

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of

Dune D. Lachner

(Division Sign-Off) Division of Cardiovascular Devices

510(k) Number_K 09162

Regulation Number and Section

§ 870.3470 Intracardiac patch or pledget made of polypropylene, polyethylene terephthalate, or polytetrafluoroethylene.

(a)
Identification. An intracardiac patch or pledget made of polypropylene, polyethylene terephthalate, or polytetrafluoroethylene is a fabric device placed in the heart that is used to repair septal defects, for patch grafting, to repair tissue, and to buttress sutures.(b)
Classification. Class II (performance standards).